Back to search results

Observational Study on Stem Cell Transplant for Acute Leukemia

This study is looking at how many patients with newly diagnosed or relapsed acute leukemia (a type of blood cancer) receive a stem cell transplant. Researchers want to understand why some patients get a transplant and others don't, even when it's recommended by their doctors. They will be assessing laboratory results that are part of standard care, including HLA allele typing (a test to match donors for transplant). The main goal is to see how many patients proceed to transplant over three years. You may be able to join if you are between 18 and 80 years old and have newly diagnosed or relapsed acute leukemia, or certain types of MDS, MPN, or MDS/MPN overlap conditions. The study is currently unclear on its recruitment status.

Study design
This is an observational study planning to enroll 1365 participants. It is not a treatment study, but rather looks at existing medical practices.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for three years to see if they proceed to transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02677064

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Recruiting
Not specifiedAges 18–80Observational
Memorial Sloan Kettering Cancer Center
~1,365 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:assessments

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
number of patients who proceed to transplant
Measured over 3 years

Conditions

Acute Leukemia
Newly Diagnosed
Relapsed

Explore related trials

Acute LeukemiaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative disorder

Where it's being run

3 sites across 3 states
Connecticut1
New York1
Pennsylvania1

Study leadership

  • Roni Tamari, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Roni Tamari, MD
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with newly diagnosed or relapsed acute leukemia. Patients undergoing reinduction due to primary induction failure are also eligible. Patients with acute leukemia will be enrolled to Arm A
Patients with diagnosis of MDS, MPN and MDS/MPN overlap who meet any of the following criteria (based on NCCN guidelines):
Clinically significant cytopenia of at least 2 cell lines affected; Hgb\<10,
Platelet\<100,000, absolute neutrophil count\<1000
Bone marrow blasts \>5% and any level of circulating blasts
Evidence of disease progression or no response to hypomethylating agents/immunosuppressive treatment or a clinical trial.
IPSS Intermediate-1 and higher
IPSS-R intermediate and higher
All cases of therapy related MDS with excess blasts
In patients with Myelofibrosis: Low risk disease by DIPSS with either refractory, transfusion dependent anemia, circulating blasts cells greater than 2%; or adverse cytogenetics and any patient with DIPSS-intermediate 1 and higher. For patients with post-PV and post-ET myelofibrosis, any patient with MYSEC-PM Intermediate-1 risk or higher is eligible.
Patients with acute leukemia or MDS/MPN who relapse after first allografts. Patients with post-transplant relapse will be enrolled to Arm C.
Patients 18 years of age or older and 80 years of age or younger
For the purposes of this protocol "relapse" is defined as re-emergence of the initial abnormal myeloid blast population (or blast equivalent) comprising 5% or more of marrow WBC or any amount prompting a therapeutic intervention targeting relapsed disease, including, but not limited to withdrawal of immunosuppression, targeted therapies, chemotherapy, etc.
Patients previously enrolled in Arm A or Arm B who experience post-transplant relapse are also eligible for enrollment onto Arm C

Exclusion

Patients with polycythemia vera (PV) and essential thrombocytosis (ET)

What this trial measures

  • number of patients who proceed to transplant3 years

    determine whether an individual patient proceeded to HCT when he or she was considered eligible (based on NCCN guidelines.